Chronic myelomonocytic leukemia (CMML) is a relatively rare clonal hematologic disorder. In the World Health Organization classification, it is listed as a disorder with features of both myelodysplastic syndromes and myeloproliferative neoplasms.
Can be variable but many patients tend to present with fatigue, weight loss, fever, and night sweats.
It is usually characterized by accumulation of monocytes in the blood and bone marrow, dysplastic hematopoiesis.
The diagnosis is characterized by:
- peripheral monocytosis (>1x109/L)
- absence of Philadelphia chromosome and BCR/ABL fusion gene
- fewer than 20% lymphoblasts in the blood or bone marrow
- dysplasia involving one or more myeloid lineages
Treatment and prognosis
The clinical course is variable. There is potential for leukemic involvement of organs. Blood transfusions and erythropoietin (EPO) administration may play a role in correcting low hemoglobin levels in cases with anemia.
- 1. Hyams ES, Gupta R, Melamed J et-al. Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy. Rev Urol. 2011;11 (1): 33-7. Free text at pubmed - Pubmed citation
- 2. Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML)-a myelodysplastic or myeloproliferative syndrome?. Leuk. Lymphoma. 2015;9 (1-2): 35-41. doi:10.3109/10428199309148501 - Pubmed citation
- 3. Derlin T, Clauditz TS, Bannas P. 18F-FDG PET/CT for staging and detection of extramedullary organ involvement in chronic myelomonocytic leukemia. Clin Nucl Med. 2014;39 (9): 811-2. doi:10.1097/RLU.0b013e3182a77c99 - Pubmed citation